Fixed Duration Combination Therapy with Carfilzomib, Lenalidomide, and Dexamethasone Followed By Lenalidomide Maintenance Leads to High Rates of Sustained MRD Negativity in Patients with High-Risk Smoldering Multiple Myeloma: Long Term Follow up of an Investigator Initiated Phase 2 Trial
Elizabeth Hill(University of Maryland, Baltimore), Dickran Kazandjian(United States Food and Drug Administration), Barış Türkbey(National Institutes of Health), Joseph Roswarski(Georgetown University), Seth M. Steinberg(National Institutes of Health), Mark Roschewski(National Cancer Institute), Katherine R. Calvo(National Institutes of Health Clinical Center), Alexander Dew(National Institutes of Health), Maryalice Stetler‐Stevenson(National Cancer Institute), Raul C. Braylan(Center for Cancer Research), Esther Mena(National Institutes of Health), Ani Petrosyan(National Institutes of Health), William D. Figg(National Cancer Institute), Liza Lindenberg(National Cancer Institute), Ola Landgren(University of Miami Health System), Nisha Patel(National Institutes of Health), Ryan M. Young(Denver Health Medical Center), Amrit Bhaskarla, Hao‐Wei Wang(Fu Jen Catholic University), Irina Marić(Center for Cancer Research), Michael Emanuel(National Institutes of Health), Alina Dulau‐Florea(National Institutes of Health), Candis Morrison(National Institutes of Health), Constance M. Yuan(National Cancer Institute)
Cited by 6
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Oncogenically active MYD88 mutations in human lymphoma
|Nature|2010|1.5k